Results 151 to 160 of about 766,604 (355)
Effect of glucocorticoids on chronic human immunodeficiency virus (HIV) infection and HIV promoter-mediated transcription [PDF]
Jeffrey Laurence, MB Sellers, S K Sikder
openalex +1 more source
Aim Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).
Allan Kengo +10 more
wiley +1 more source
Progressive neurological dysfunction during latent HIV infection. [PDF]
Janus Christian Jakobsen +4 more
openalex +1 more source
Aims Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Eleanor G. Dixon +10 more
wiley +1 more source
Opportunistic infection among HIV seropositive cases in Manipal Teaching Hospital, Pokhara, Nepal
BA Dhungel +3 more
openalex +2 more sources
People accessing aged care services are increasingly older and often experience multimorbidity and polypharmacy, which puts them at risk of medication‐related harm. Quality indicators (QIs) can assist with monitoring, benchmarking and informing initiatives to reduce medication‐related harm.
Daria S. Gutteridge +20 more
wiley +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Oral Manifestations of HIV Infections - A Review
Mst Fatema Akhter +5 more
openalex +2 more sources
Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment. [PDF]
R A Hague +7 more
openalex +1 more source
Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels
This review examines the PGx annotations in package inserts (bulas in Brazilian Portuguese) approved by ANVISA, the Brazilian Health Regulatory Agency, for 19 gene–drug pairs with strong or moderate recommendations for initial dosing alteration in the CPIC (Clinical Pharmacogenetic Implementation Consortion) guidelines and PGx testing required or ...
Guilherme Suarez‐Kurtz
wiley +1 more source

